Skip to content

Observation and Research on the Efficacy of Hydrogen in Rheumatoid Foot

Evaluation of the Efficacy of Inhaled Hydrogen in Patients with Rheumatoid Foot

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097235
Enrollment
Unknown
Registered
2025-02-14
Start date
2024-01-10
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid foot

Interventions

Hydrogen inhalation group:Inhale a hydrogen - oxygen mixed gas (67% H? + 33% O?, automatically mixed and produced by the hydrogen - oxygen generator in a 2:1 ratio)
Placebo group:Inhale oxygen (33% O?, a mixture of 0.5 L of pure oxygen and 2.5 L of air, automatically produced by the hydrogen - oxygen machine)

Sponsors

The Second Affiliated Hospital of Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed as a patient with rheumatoid arthritis (RA) according to the "2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis" and in the active stage of the disease. (2) RA accompanied by foot manifestations: hallux valgus deformity, dislocation/subluxation of the 2nd - 5th metatarsophalangeal joints. (3) The patient's age ranges from 40 to 65 years old. (4) No drug treatment has been received, or drugs such as methotrexate (MTX) have been discontinued for at least 4 weeks.

Exclusion criteria

Exclusion criteria: (1) Loss of foot sensation. (2) Pain caused by diseases such as lumbar disc herniation or peripheral neuropathy. (3) Simple or congenital hallux valgus deformity. (4) Complicated with other arthritic lesions, such as gouty arthritis, osteoarthritis, and rheumatic arthritis. (5) Exclude other synovial lesions of joints: synovial tuberculosis, synovial chondromatosis, etc.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;Health Assessment Questionnaire;

Secondary

MeasureTime frame
joint synovial thickness;serum inflammatory factors;

Countries

China

Contacts

Public ContactDingXiaolin

The Second Affiliated Hospital of Shandong First Medical University

ankle163@163.com+86 156 6608 2271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026